Articles From This Issue
By Joshua Robinson, MD
Cover Stories: The Turning Point
The road that brought Joshua Robinson, MD, to private practice at Palmetto Retina Center in West Columbia, S.C. was long and winding. If given the chance, however, he says he …
By Jonathan L. Prenner, MD, and Richard S. Kaiser, MD
Have you ever been out on an open body of water and jumped in? It can be nerve-wracking when you cannot see the bottom -- or anything past the surface, really. The feeling…
Supplements and Inserts
By CARL D. REGILLO, MD
One of the key components of successful and safe retina surgery is the ability to engage target tissue while causing minimal or no disruption of adjacent tissue. Whether dissecting hyaloid near the retina, peeling a membrane, or performing core vitrectomy, the surgeon must be ever mindful of tractional forces and how much stress the intraocular maneuvers are placing on the retina-vitreous interface.
By Charles C. Wykoff, MD, PhD, moderator; Caroline R. Baumal, MD; David Eichenbaum, MD; and Chirag P. Shah, MD, MPH
The prevalence of diabetes is growing globally; as such the number of people affected by vision-threatening diabetic retinopathy (DR) is likewise expected to continue to increase. Prevent Blindness America has estimated more than 7.6 million people in the United States have DR as a result of their systemic disorder.1
By FIRAS M. RAHHAL, MD
The majority of my cases are operated using 23-gauge instrumentation using valved cannulas whenever possible. While I do use some 25-gauge, I prefer to use the technology with which I am most comfortable. I am not necessarily resistant to change; however, I have been getting very good results with my particular setup for over a decade, and so it is difficult for me to justify modifying my approach.
Vortex Surgical announced the release of its latest offering, the Vortex Surgical Convenience Kit. Launched during the annual meeting of the American Academy of Ophthalmology in New Orleans, the produ…
At the American Academy of Ophthalmology meeting in New Orleans, Novartis announced positive results from two phase 3 studies (HAWK and HARRIER) of brolucizumab versus Regeneron's aflibercept (Eyl…